NCT07827456Not yet recruiting
MRI-Guided Temporal Interference Stimulation for Parkinson's Disease
Efficacy of MRI-Guided Transcranial Temporal Interference Electrical Stimulation (tTIS) Modulation for Parkinson's Disease: An Exploratory Study
Source: ClinicalTrials.gov · Last updated 21 Sept 2026
Brief summary (registry, in English)
This study aims to evaluate the efficacy and safety of tTIS treatment in patients with Parkinson's disease (PD). The study will enroll eligible PD patients and randomly assign them to two groups: Group A will first receive combined GPi and STN stimulation, followed by GPi stimulation one week later; Group B will first receive GPi stimulation, followed by combined GPi and STN stimulation one week later. The MDS-UPDRS Part III will be assessed at pre-stimulation baseline, immediately after stimulation, and at 30 and 60 minutes post-stimulation for each session, in order to evaluate and compare the therapeutic effects of tTIS targeting GPi alone versus combined GPi and STN stimulation on motor symptoms in PD patients, and to assess the differential efficacy of tTIS at different targets among PD patients with varying symptoms.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 26 (estimated)
- First submitted
- 14 Sept 2026
- Start date
- 15 Sept 2026
- Primary completion date
- 10 Jun 2027
- Lead sponsor
- Tongji Hospital
- Diseases
- Parkinson disease
- NCT number
- NCT07827456
What you commit to
- Study type: Interventional
- Planned participants: 26
- From 15 Sept 2026 to the primary completion date, 10 Jun 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Presence of metallic implants in the brain;
Other illness
- Presence of a significant medical condition that may interfere with study procedures or confound the assessment of study endpoints;
- Presence of a severe psychiatric disorder that may affect the participant's ability to comply with the study protocol;
- A history of psychiatric disorders or current severe depression or anxiety;
- Severe neurological disorders, such as a brain tumor;
- Severe cardiac disease, including the presence of an implanted cardiac pacemaker;
- Scalp lesions, inflammation, infection, active bleeding, or an increased bleeding tendency;
- Any other current medical condition for which the use of transcranial electrical stimulation may pose an unacceptable risk;
- A history of epilepsy or structural brain lesions, including severe cerebral atrophy or cerebrovascular disease;
- Inability to cooperate with or complete the required assessments; or any other condition that, in the investigator's judgment, makes the individual unsuitable for participation in the study.
Other
- Inability or unwillingness to comply with the study protocol and/or inability to provide written informed consent;
- Known pregnancy or current breastfeeding;
- Inability to undergo magnetic resonance imaging (MRI), such as because of claustrophobia or implanted metallic devices;
Who the study is looking for
- Age 18-75 years (inclusive), any gender.
- Diagnosis of idiopathic Parkinson's disease according to the Chinese diagnostic criteria for Parkinson's disease (2016 edition).
- Hoehn and Yahr stage 2-4 (inclusive) during the "off" state.
- Documented response to levodopa (\>33% improvement), with a stable anti-parkinsonian medication regimen for at least 4 weeks prior to screening, and no dose adjustments during the study.
- Voluntary signed informed consent, and ability to understand and comply with the study protocol to complete the study.
- No significant cognitive impairment (Montreal Cognitive Assessment \[MoCA\] score ≥21).
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.